News

January 30, 2019

Baseline and Interim PET Scans May Predict Long-Term Survival of PTCL Patients, Study Shows

News

Higher tumor volume at baseline and worse responses to chemotherapy after four cycles — measured with positron emission tomography (PET) scans — can predict poorer overall and event-free survival among ... Read more

January 29, 2019

Gamida Cell, Be The Match BioTherapies Team Up on NiCord for Blood Cancers

News

A collaboration between cellular and immune therapeutics firm Gamida Cell and Be The Match BioTherapies is designed to widen the use of bone marrow transplants to treat blood cancers. The partnership ... Read more

January 28, 2019

FDA Names Umbralisib ‘Breakthrough Therapy’ as Possible Treatment for Marginal Zone Lymphoma

News

The U.S. Food and Drug Administration (FDA) has designated umbralisib (TGR-1202), by TG Therapeutics, a breakthrough therapy as a possible treatment for adults with marginal zone lymphoma (MZL) who did not respond to at least one ... Read more

January 25, 2019

2 Chemo Regimens Used Before Stem Cell Transplant Have Similar Effectiveness, Study Finds

News

A chemotherapy regimen called modified busulfan-cyclophosphamide (mBuCy) — which consists of busulfan, cyclophosphamide, semustine, and cytarabine — is as effective as standard chemotherapy in preparing lymphoma patients for a stem cell ... Read more

January 24, 2019

Imbruvica-Opdivo Combination Shows Promise in Richter’s Transformation

News

A combination of Imbruvica (ibrutinib) and Opdivo (nivolumab) reduced tumor burden in 65% of patients with Richter’s transformation — a kind of diffuse large B-cell lymphoma (DLBCL) with very poor prognosis, derived ... Read more

January 23, 2019

Genetic Profiling Identifies DLBCL Patients in Need of More Aggressive Treatment, Study Reports

News

Investigators in the U.K. have found a way to identify diffuse large B-cell lymphoma (DLBCL) patients who are less likely to respond to standard therapies and may require more aggressive ... Read more

January 22, 2019

Childhood Hodgkin’s Lymphoma Survivors At Higher Risk for Cancer Later in Life, Study Shows

News

Survivors of childhood Hodgkin’s lymphoma are 14 times more likely to develop a subsequent solid tumor than the general population, and this risk remains high for several decades post-diagnosis, a ... Read more

January 21, 2019

LOXO-305 Trial Begins for Lymphoma, Leukemia Patients Resistant to BTK Inhibitors

News

A Phase 1/2 trial is evaluating Loxo Oncology‘s BTK inhibitor LOXO-305 in leukemia and lymphoma patients who failed, or were intolerant to, approved BTK inhibitors. The trial, so far being conducted ... Read more

January 18, 2019

Tyvyt, PD-1 Inhibitor Newly Approved in China, Showed Efficacy Similar to Opdivo and Keytruda, Trial Data Show

News

The immune checkpoint inhibitor Tyvyt (sintilimab injection) reduced tumor burden in eight out of 10 people with relapsed or refractory classic Hodgkin’s lymphoma taking part in a Phase 2 clinical ... Read more

January 17, 2019

FDA Grants Breakthrough Therapy Designation to Zanubrutinib for Mantle Cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to BeiGene’s zanubrutinib as a treatment candidate for adults with mantle cell lymphoma (MCL) who have received at least ... Read more